Developing a Total Healthcare Business From Prevention Through Testing, Diagnosis and Treatment
First written in FY2022-Q1. 3 of 7 entries say "Advanced", first in 2026-03-23. Latest entry: 2026-10-01.
0 other companies' latest entry also says "Advanced".
- 2026-10-01AdvancedGovernance
「各事業の連携により予防・検査・診断・治療・予後にわたる価値創造を実現するとともに、「ASKA VISION 2035」の達成に向けて持続的な成長を推進しています。」
トータルヘルスケアの範囲を、5事業間の連携による予防・検査・診断・治療・予後の価値創造として具体化している。 - FY2026AdvancedAnnual report
「Under Medium-Term Management Plan 2028, we will pursue further growth based on five pillars that will drive group growth and two foundations that support them.」
The total healthcare strategy has been organized under the new Medium-Term Management Plan 2028 into five pillars and two foundations. - 2026-03-23AdvancedManagement planning
「While building on our prescription pharmaceutical business, centered on gynecology, we will strengthen drug discovery research and expand our overseas business, while also developing animal health and testing and around-the-pill businesses, to achieve sustainable growth and contribute to society.」
The total healthcare strategy was specified through growth areas including drug discovery research, overseas operations, animal health, and testing and around-the-pill businesses. - FY2024RestatedAnnual report
「Building on our existing businesses, we aim to become a total healthcare company operating domestically and internationally across the entire healthcare market, covering prevention, testing and diagnosis, treatment and post-treatment care.」
The company’s policy of developing a total healthcare business in Japan and overseas covering prevention, testing and diagnosis, treatment and post-treatment care is reaffirmed. - FY2023RestatedAnnual report
「Building on our existing businesses, we aim to become a total healthcare company operating domestically and internationally across the entire healthcare market, covering prevention, testing and diagnosis, treatment and post-treatment care.」
The policy of developing a total healthcare business in Japan and overseas covering prevention, testing and diagnosis, treatment and post-treatment care is reiterated. - FY2022RaisedAnnual report
「Building on our existing businesses, we aim to become a total healthcare company operating domestically and internationally across the entire healthcare market, covering prevention, testing and diagnosis, treatment and post-treatment care.」
The scope has been expanded beyond prevention, testing, diagnosis and treatment to include post-treatment care and operations across domestic and international healthcare markets. - FY2022-Q1First statedAnnual report
「To respond to social changes in attitudes toward health and healthcare needs, we view healthcare comprehensively as a connected framework spanning prevention, testing and diagnosis, and treatment, and will develop related businesses.」
The company indicates that it will develop related businesses across prevention, testing and diagnosis, and treatment as an integrated framework rather than focusing solely on pharmaceuticals.